The U.S. commercial availability of Penumbra’s advanced thrombectomy device, the ACE68 Reperfusion Catheter, part of the fully integrated Penumbra System, was announced at the Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting in Boston, Massachusetts.
The ACE68 Reperfusion Catheter helps deliver maximum aspiration power easily and safely for extracting thrombus in acute ischemic stroke patients.
“The tracking technology of the ACE68 Reperfusion Catheter is the most advanced,” said Blaise Baxter, M.D., chief of radiology at Erlanger Hospital in Tennessee and chairman of radiology for the University of Tennessee College of Medicine Chattanooga. “In my clinical experience with the ACE68, I saw the device easily navigate difficult tortuosity that would have challenged other devices.”
The ACE68 Reperfusion Catheter was engineered on a new tracking platform from hub to tip. Featuring a unique coil winding geometry along 16 transitions to create the optimal tracking profile, ACE68 is designed to ensure easy tracking through tortuosity that is typical in acute ischemic stroke patients. ACE68 is powered to extract clot en masse quickly and effectively as part of the fully integrated Penumbra System.
“The ACE68’s large lumen increases the likelihood of capturing the clot fully within the catheter or the canister, potentially reducing the number of passes to achieve complete revascularization and minimize ENT (embolization to new territory),” said Johanna Fifi, M.D., assistant professor of neurology, neurosurgery and radiology at The Mount Sinai Hospital and director of the Endovascular Stroke Program at the Mount Sinai Health System in New York.
The ACE68 represents the latest advances in tracking technology to deliver a large bore reperfusion catheter easily and reliably through tortuosity that is typical in acute ischemic stroke patients.
